A West Virginia court ruled in favor of Merck in the drug company's lawsuit against Canonsburg, Pa.-based Viatris, which accused the drugmaker of infringing on two of Merck's patents.
Viatris submitted two drug applications to the FDA that were generics for three of Merck's type 2 diabetes drugs that have exclusivity until Nov. 24, 2026, Merck said in a Sept. 22 news release. The second patent, which is for its diabetes drug Janumet, is set to expire in 2029.